Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
Company profile
Ticker
OPNT
Exchange
Website
CEO
Roger Crystal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Lightlake Therapeutics Inc., Madrona Ventures, Inc.
SEC CIK
OPNT stock data
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
11 Jul 23
15-12G
Securities registration termination
13 Mar 23
EFFECT
Notice of effectiveness
10 Mar 23
EFFECT
Notice of effectiveness
10 Mar 23
EFFECT
Notice of effectiveness
10 Mar 23
POS AM
Prospectus update (post-effective amendment)
6 Mar 23
POS AM
Prospectus update (post-effective amendment)
6 Mar 23
POS AM
Prospectus update (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
Transcripts
OPNT
Earnings call transcript
2022 Q2
12 Aug 22
OPNT
Earnings call transcript
2022 Q1
14 May 22
OPNT
Earnings call transcript
2021 Q4
15 Mar 22
OPNT
Earnings call transcript
2021 Q3
12 Nov 21
OPNT
Earnings call transcript
2021 Q2
7 Aug 21
OPNT
Earnings call transcript
2021 Q1
11 May 21
OPNT
Earnings call transcript
2020 Q4
5 Mar 21
OPNT
Earnings call transcript
2020 Q3
12 Nov 20
OPNT
Earnings call transcript
2020 Q2
9 Aug 20
OPNT
Earnings call transcript
2020 Q1
12 May 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.38 mm | 35.38 mm | 35.38 mm | 35.38 mm | 35.38 mm | 35.38 mm |
Cash burn (monthly) | 1.60 mm | (no burn) | 3.30 mm | 2.71 mm | 1.58 mm | 1.29 mm |
Cash used (since last report) | 30.07 mm | n/a | 62.11 mm | 50.97 mm | 29.72 mm | 24.24 mm |
Cash remaining | 5.30 mm | n/a | -26.73 mm | -15.60 mm | 5.66 mm | 11.14 mm |
Runway (months of cash) | 3.3 | n/a | -8.1 | -5.8 | 3.6 | 8.6 |
Institutional ownership, Q1 2023
0.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 35 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 104.00 k |
Total shares | 13.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Radoff Bradley Louis | 13.00 k | $104.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Mar 23 | O'Toole David D | Common Stock | Sale back to company | Dispose D | No | No | 20 | 2,000 | 40.00 k | 0 |
2 Mar 23 | O'Toole David D | Common Stock | Grant | Acquire A | No | No | 0 | 2,000 | 0.00 | 2,000 |
2 Mar 23 | O'Toole David D | Common Stock | Sale back to company | Dispose D | No | No | 20 | 11,736 | 234.72 k | 0 |
2 Mar 23 | O'Toole David D | Common Stock | Sale back to company | Dispose D | No | No | 20 | 22,512 | 450.24 k | 11,736 |
2 Mar 23 | O'Toole David D | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.15 | 10,750 | 130.61 k | 0 |
2 Mar 23 | O'Toole David D | Common Stock Common Stock | Sale back to company | Dispose D | No | No | 13.6 | 8,250 | 112.20 k | 0 |
2 Mar 23 | O'Toole David D | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 13.61 | 33,000 | 449.13 k | 0 |
2 Mar 23 | Thomas Thomas T. | Common Stock | Sale back to company | Dispose D | No | No | 20 | 2,000 | 40.00 k | 0 |
2 Mar 23 | Thomas Thomas T. | Common Stock | Sale back to company | Dispose D | No | No | 20 | 10,375 | 207.50 k | 2,000 |
2 Mar 23 | Thomas Thomas T. | Common Stock Common Stock | Sale back to company | Dispose D | No | No | 8.79 | 2,500 | 21.98 k | 0 |